AstraZeneca news from FierceBiotech
NewsMedImmune’s Mott heads for the exit
David Mott, the CEO of MedImmune who led his company through a $15.6 billion buyout by AstraZeneca, is leaving the company a year after the deal closed. Mott says he's leaving for personal reasons Read more...
Elan wins $55M judgment in patent scrap
Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent. Read more...
DPP-4 inhibitors get spotlight at ADA meeting
Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood Read more...
SPOTLIGHT: Fortune snubs Big Pharma in employers list
Looking for the best employers? Don't look at Big Pharma. The annual Fortune magazine list of the 100 "Best Companies to Work For" contains only one Big Pharma name: AstraZeneca, at No. 83. Read more...
MedImmune to hire 800 in pipeline push
With plans to double the number of experimental therapies in its pipeline by 2010, MedImmune is laying plans to hire 800 new staffers by the end of this year, according to a report in the Washington Read more...
ALSO NOTED: BioSeek to collaborate with Merck KGaA; BioAlliance acquires drug rights; and much more...
> BioSeek has forged a collaboration deal with Merck KGaA to evaluate the potential of small molecules and proteins. Read more...
Biotech M&A has yet to reach its peak
In analyzing the PowerShares Dynamic Biotech & Genome ETF, a fund made up of primarily small- and medium-cap biotech stocks, Seeking Alpha notes that Big Pharma's appetite for biotech Read more...
Sepracor inks $47M IP licensing deal with Arrow
Sepracor has struck a licensing deal with Arrow International Limited for the intellectual property rights related to stable sterile steroid suspension formulations and other applicable nebule Read more...
Biopharma execs sign on to tout UK's R&D work
A high-profile crew of biopharma execs are signing on to help promote the life sciences industry in the UK. Chris Brinsmead, president of AstraZeneca U.K., will chair a 12-man strategy group for UK Read more...
Can Big Pharma effectively develop new drugs?
When it comes to drug development, is bigger really better? That is the question Borje Eckholm, president and CEO of Investor AB--and one of AstraZeneca's biggest shareholders--poses in the London Read more...
| Press ReleasesPRESS RELEASE: AstraZeneca Files Patent Infringement Actions in Response to Crestor™ ANDAs AstraZeneca Files Patent Infringement Actions in Response to Crestor™ ANDAs AstraZeneca today announced that it has filed patent infringement actions in United States District Court, District of Read more... PRESS RELEASE: FDA's Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events FDA's Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events Background: On May 29, 2007 AstraZeneca, the maker of Prilosec (omeprazole) and Nexium Read more... PRESS RELEASE: AstraZeneca Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and Investor R&D Day AstraZeneca Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and Investor R&D Day AstraZeneca (AZN) today holds an R&D day for analysts and investors at the Read more... PRESS RELEASE: AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL The first data from the SEROQUEL XR™ (quetiapine fumarate) Extended Release clinical development programme in major depressive Read more... PRESS RELEASE: AstraZeneca Receives Six Months Paediatric Exclusivity Patent Extension For ARIMIDEX From The FDA AstraZeneca Receives Six Months Paediatric Exclusivity Patent Extension For ARIMIDEX From The FDA AstraZeneca today announced that the United States (US) Food and Drug Administration (FDA) has Read more... |
Get more AstraZeneca coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends